The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00071472" target="_blank" >RIV/00216224:14110/13:00071472 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/65269705:_____/13:#0002129 RIV/00023001:_____/13:00058644 RIV/75010330:_____/13:00010098 RIV/00216208:11120/13:43907545 a 2 dalších
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s00280-013-2246-2" target="_blank" >http://dx.doi.org/10.1007/s00280-013-2246-2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00280-013-2246-2" target="_blank" >10.1007/s00280-013-2246-2</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Popis výsledku v původním jazyce
The aim of this study was to investigate the prognostic significance of fourteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and confirmed by sequencing. SLC22A3 and SLC22A18 were upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis.
Název v anglickém jazyce
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Popis výsledku anglicky
The aim of this study was to investigate the prognostic significance of fourteen anticancer drug-relevant solute carrier transporters (SLCs) in pancreatic cancer in the context of clinical-pathological characteristics and the KRAS mutation status of tumors. Tumors and non-neoplastic pancreatic tissues were obtained from 32 histologically verified patients with pancreatic ductal adenocarcinoma. The transcript profile of SLCs was assessed using quantitative real-time PCR. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and confirmed by sequencing. SLC22A3 and SLC22A18 were upregulated and SLC22A1, SLC22A2, SLC22A11, SLC28A1, SLC28A3 and SLC29A1 were downregulated when compared with non-neoplastic pancreatic tissues. Moreover, significantly lower levels of SLC22A1, SLC22A11 and SLC29A1 were found in tumors with angioinvasion. There was also a significantly higher transcript level of SLC28A1 in tumors with regional lymph nodes affected by metastasis.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN
0344-5704
e-ISSN
—
Svazek periodika
72
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
14
Strana od-do
669-682
Kód UT WoS článku
000323653600019
EID výsledku v databázi Scopus
—